Retinitis Pigmentosa News and Research

RSS
Retinitis pigmentosa (RP) is the name given to a group of inherited eye diseases that affect the retina (the light-sensitive part of the eye). RP causes the breakdown of photoreceptor cells (cells in the retina that detect light). Photoreceptor cells capture and process light helping us to see. As these cells breakdown and die, patients experience progressive vision loss. The most common feature of all forms of RP is a gradual breakdown of rods (retinal cells that detect dim light) and cones (retinal cells that detect light and color). Most forms of RP first cause the breakdown of rod cells. These forms of RP, sometimes called rod-cone dystrophy, usually begin with night blindness. Night blindness is somewhat like the experience normally sighted individuals encounter when entering a dark movie theatre on a bright, sunny day. However, patients with RP cannot adjust well to dark and dimly lit environments.
Eye drops show potential to slow progression of human degenerative retinal diseases

Eye drops show potential to slow progression of human degenerative retinal diseases

JAX researchers identify key genetic factors influencing eye aging in mice

JAX researchers identify key genetic factors influencing eye aging in mice

New compounds show promise in treating retinitis pigmentosa

New compounds show promise in treating retinitis pigmentosa

Researchers discover how mutations disrupt protein splicing and cause disease

Researchers discover how mutations disrupt protein splicing and cause disease

Researchers discover mechanism affecting splicing process in retinal cells

Researchers discover mechanism affecting splicing process in retinal cells

Genetic diagnosis solves medical mystery for 30 undiagnosed patients

Genetic diagnosis solves medical mystery for 30 undiagnosed patients

Drug repurposing offers hope for SYNGAP1 patients

Drug repurposing offers hope for SYNGAP1 patients

Unlocking the secrets of Usher syndrome

Unlocking the secrets of Usher syndrome

New drug targets identified for retinitis pigmentosa therapies

New drug targets identified for retinitis pigmentosa therapies

Case Western Reserve University receives $1.5M grant for oral drug trial to prevent blindness in RP patients

Case Western Reserve University receives $1.5M grant for oral drug trial to prevent blindness in RP patients

RPGRIP1L gene expression levels can be a potential prognostic marker for invasive breast cancer

RPGRIP1L gene expression levels can be a potential prognostic marker for invasive breast cancer

Soft ERG multi-electrode system developed for enhanced eye disease monitoring

Soft ERG multi-electrode system developed for enhanced eye disease monitoring

ZIP7: A novel target for treating degenerative diseases associated with misfolded proteins

ZIP7: A novel target for treating degenerative diseases associated with misfolded proteins

From China to Uzbekistan - United for Women’s Wellness on IWD

From China to Uzbekistan - United for Women’s Wellness on IWD

Gut bacteria may be responsible for sight loss in certain inherited eye diseases

Gut bacteria may be responsible for sight loss in certain inherited eye diseases

Study sheds light on 7-DHC's potential to induce cell death-resistant state in tumors

Study sheds light on 7-DHC's potential to induce cell death-resistant state in tumors

Engineered virus-like particles power up gene editing, correcting blindness in mice

Engineered virus-like particles power up gene editing, correcting blindness in mice

Revolutionary approach links protein analysis and single-cell study to uncover disease mechanisms

Revolutionary approach links protein analysis and single-cell study to uncover disease mechanisms

Stanford Medicine researchers find new way to measure ocular aging

Stanford Medicine researchers find new way to measure ocular aging

Researchers identify key mechanisms to address future treatments for hereditary blindness

Researchers identify key mechanisms to address future treatments for hereditary blindness

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.